Amgenvs.BioMarin Pharmaceutical
AMGN vs BMRN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Amgen is about 21× larger than BioMarin Pharmaceutical by market cap; Amgen trades at the lower P/E (25.2 vs 144.9); year to date, Amgen leads (+26.2% vs −7.6%).
Side by side
| AMGN | BMRN | |
|---|---|---|
| Market cap | $220B | $10.6B |
| Price | $414.87 | $54.80 |
| Today | +1.8% | −0.2% |
| Return YTD | +26.2% | −7.6% |
| Return 1Y | +39.8% | +0.4% |
| Since June 26, 2026 | +15.8% | −7.1% |
| P/E | 25.2 | 144.9 |
| P/S | 5.8 | 3.1 |
| P/B | 18.8 | 1.7 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
AmgenAMGN
Long-established in biotech, with oncology and haematology at the centre of the portfolio, immunology beside it and a line in bone disease. MariTide is the obesity candidate in the pipeline.
Full AMGN profile →BioMarin PharmaceuticalBMRN
Rare genetic disorders define the company. It sells enzyme replacement therapies and Voxzogo for dwarfism, and has taken gene therapy into hemophilia.
Full BMRN profile →More AMGN & BMRN comparisons
Other head-to-heads in the Biotech & innovation segment.